AR094084A1 - El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en el tratamiento de la aterosclerosis - Google Patents
El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en el tratamiento de la aterosclerosisInfo
- Publication number
- AR094084A1 AR094084A1 ARP130104820A ARP130104820A AR094084A1 AR 094084 A1 AR094084 A1 AR 094084A1 AR P130104820 A ARP130104820 A AR P130104820A AR P130104820 A ARP130104820 A AR P130104820A AR 094084 A1 AR094084 A1 AR 094084A1
- Authority
- AR
- Argentina
- Prior art keywords
- dimethylpropan
- aminium
- treatment
- pharmaceutically acceptable
- aterosclerosis
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
El uso de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio y de sus sales farmacéuticamente aceptables: fumarato de hidrógeno de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio y fosfato de dihidrógeno 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio, en la prevención y el tratamiento de la aterosclerosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094084A1 true AR094084A1 (es) | 2015-07-08 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104820A AR094084A1 (es) | 2012-12-20 | 2013-12-18 | El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en el tratamiento de la aterosclerosis |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (es) |
| AR (1) | AR094084A1 (es) |
| BR (1) | BR112015014161B1 (es) |
| CA (1) | CA2895574C (es) |
| CU (1) | CU20150067A7 (es) |
| JO (1) | JO3117B1 (es) |
| MX (1) | MX362762B (es) |
| PE (1) | PE20151587A1 (es) |
| TN (1) | TN2015000236A1 (es) |
| WO (1) | WO2014096133A1 (es) |
| ZA (1) | ZA201505093B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| CA2766048A1 (en) * | 2009-06-25 | 2010-12-29 | Tetra, Sia | Novel acetylsalicylic acid salts |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| RS55092B1 (sr) * | 2011-04-27 | 2016-12-30 | Grindeks Jsc | Upotreba 3-karboksi-n-etil-n,n-dimetilpropan-1-aminijum soli u lečenju kardiovaskularne bolesti |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/ar active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/es unknown
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/pt active IP Right Grant
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/zh active Active
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/es not_active Application Discontinuation
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en not_active Ceased
- 2013-12-19 MX MX2015008138A patent/MX362762B/es active IP Right Grant
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/fr unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/es unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104869988A (zh) | 2015-08-26 |
| BR112015014161B1 (pt) | 2021-02-17 |
| MX2015008138A (es) | 2016-04-25 |
| CN104869988B (zh) | 2017-07-28 |
| ZA201505093B (en) | 2016-04-28 |
| BR112015014161A2 (pt) | 2017-07-11 |
| PE20151587A1 (es) | 2015-12-05 |
| TN2015000236A1 (en) | 2016-10-03 |
| CU20150067A7 (es) | 2016-01-29 |
| WO2014096133A1 (en) | 2014-06-26 |
| JO3117B1 (ar) | 2017-09-20 |
| MX362762B (es) | 2019-02-06 |
| CA2895574C (en) | 2019-11-26 |
| CA2895574A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| CL2016002971A1 (es) | Combinación. | |
| CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
| EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| UY34720A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo | |
| ECSP14007644A (es) | Composiciones intranasales de dexmedetomidina y métodos de uso de ellas | |
| SG10201806787VA (en) | Modulators of complement factor b | |
| CL2015001461A1 (es) | Una formulación estabilizada de pemetrexed. | |
| CR20150211A (es) | Compuestos diméricos | |
| MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| UY4223Q (es) | Banco | |
| PH12017501071B1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| MX374220B (es) | Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados. | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| UY4243Q (es) | Banco | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| MX363558B (es) | Composiciones farmaceuticas que comprenden flurbiprofeno. | |
| AR094084A1 (es) | El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en el tratamiento de la aterosclerosis | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| CY1119212T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης | |
| AR095890A1 (es) | Uso de ácido trifluoroacético y sales del mismo para tratar la hipercolesterolemia | |
| CR20140526A (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |